{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:20:26Z","timestamp":1790436026088,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia in blast crisis (CML BC) remains a challenging disease to treat despite the introduction and advances in tyrosine kinase inhibitor (TKI) therapy. In this study we set out to identify novel candidate drugs for CML BC by using an unbiased high-throughput drug testing platform. We used three CML cell lines representing different types of CML blast phases (K562, EM-2 and MOLM-1) and primary leukemic cells from three CML BC patients. Profiling of drug responses was performed with a drug sensitivity and resistance testing platform comprising 295 anticancer agents. Overall, drug sensitivity scores and the drug response profiles of cell line and primary cell samples correlated well and were distinct from other types of leukemia samples. The cell lines were highly sensitive to TKIs and the clinically TKI-resistant patient samples were also resistant <jats:italic>ex vivo<\/jats:italic>. Comparison of cell line and patient sample data identified new candidate drugs for CML BC, such as vascular endothelial growth factor receptor and nicotinamide phosphoribosyltransferase inhibitors. Our results indicate that these drugs in particular warrant further evaluation by analyzing a larger set of primary patient samples. The results also pave way for designing rational combination therapies.<\/jats:p>","DOI":"10.1038\/bcj.2015.30","type":"journal-article","created":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T13:21:38Z","timestamp":1430486498000},"page":"e309-e309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing"],"prefix":"10.1038","volume":"5","author":[{"given":"P O","family":"Pietarinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Pemovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kontro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Mpindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E I","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kuusanm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Koskenvesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-0332","authenticated-orcid":false,"given":"O","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Wennerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,1]]},"reference":[{"key":"BFbcj201530_CR1","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFbcj201530_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/156800911793743637","volume":"11","author":"AA Leitner","year":"2011","unstructured":"Leitner AA, Hochhaus A, M\u00fcller MC . Current treatment concepts of CML. Curr Cancer Drug Targets 2011; 11: 31\u201343.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFbcj201530_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/asheducation-2013.1.168","volume":"2013","author":"T Hughes","year":"2013","unstructured":"Hughes T, White D . Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology Am Soc Hematol Educ Program 2013; 2013: 168\u2013175.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"BFbcj201530_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","volume":"2007","author":"J. P. Radich","year":"2007","unstructured":"Radich JP . The Biology of CML blast crisis. Hematology Am Soc Hematol Educ Program 2007, 384\u2013391.","journal-title":"Hematology"},{"key":"BFbcj201530_CR5","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013; 3: 1416\u20131429.","journal-title":"Cancer Discov"},{"key":"BFbcj201530_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0950-3536(87)80037-9","volume":"1","author":"A Keating","year":"1987","unstructured":"Keating A . Ph positive CML cell lines. Bailli\u00e8res Clin Haematol 1987; 1: 1021\u20131029.","journal-title":"Bailli\u00e8res Clin Haematol"},{"key":"BFbcj201530_CR7","first-page":"261","volume":"4","author":"Y Matsuo","year":"1991","unstructured":"Matsuo Y, Adachi T, Tsubota T, Imanishi J, Minowada J . Establishment and characterization of a novel megakaryoblastic cell line, MOLM-1, from a patient with chronic myelogenous leukemia. Hum Cell 1991; 4: 261\u2013264.","journal-title":"Hum Cell"},{"key":"BFbcj201530_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0145-2126(98)00171-4","volume":"23","author":"HG Drexler","year":"1999","unstructured":"Drexler HG, MacLeod RA, Uphoff CC . Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res 1999; 23: 207\u2013215.","journal-title":"Leuk Res"},{"key":"BFbcj201530_CR9","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep 2014; 4: 5193.","journal-title":"Sci Rep"},{"key":"BFbcj201530_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570\u2013575.","journal-title":"Nature"},{"key":"BFbcj201530_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603\u2013607.","journal-title":"Nature"},{"key":"BFbcj201530_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature12831","volume":"504","author":"B Haibe-Kains","year":"2013","unstructured":"Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJWL et al. Inconsistency in large pharmacogenomic studies. Nature 2013; 504: 389\u2013393.","journal-title":"Nature"},{"key":"BFbcj201530_CR13","first-page":"183","volume":"13","author":"S Ogawa","year":"1996","unstructured":"Ogawa S, Kurokawa M, Tanaka T, Mitani K, Inazawa J, Hangaishi A et al. Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. Oncogene 1996; 13: 183\u2013191.","journal-title":"Oncogene"},{"key":"BFbcj201530_CR14","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1038\/onc.2014.108","volume":"33","author":"T Sato","year":"2014","unstructured":"Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y et al. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Oncogene 2014; 33: 5028\u20135038.","journal-title":"Oncogene"},{"key":"BFbcj201530_CR15","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","volume":"96","author":"A Aguayo","year":"2000","unstructured":"Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240\u20132245.","journal-title":"Blood"},{"key":"BFbcj201530_CR16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.leukres.2014.01.010","volume":"38","author":"L Legros","year":"2014","unstructured":"Legros L, Guilhot J, Huault S, Mahon F-X, Preudhomme C, Guilhot F et al. Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. Leuk Res 2014; 38: 662\u2013665.","journal-title":"Leuk Res"},{"key":"BFbcj201530_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature14119","volume":"519","author":"T Pemovska","year":"2015","unstructured":"Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 2015; 519: 102\u2013105.","journal-title":"Nature"},{"key":"BFbcj201530_CR18","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.chembiol.2013.09.014","volume":"20","author":"CJ Matheny","year":"2013","unstructured":"Matheny CJ, Wei MC, Bassik MC, Donnelly AJ, Kampmann M, Iwasaki M et al. Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. Chem Biol 2013; 20: 1352\u20131363.","journal-title":"Chem Biol"},{"key":"BFbcj201530_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1248\/bpb.b13-00495","volume":"37","author":"M Takeuchi","year":"2014","unstructured":"Takeuchi M, Niimi T, Masumoto M, Orita M, Yokota H, Yamamoto T . Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening. Biol Pharm Bull 2014; 37: 31\u201336.","journal-title":"Biol Pharm Bull"},{"key":"BFbcj201530_CR20","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","volume":"111","author":"A Gontarewicz","year":"2008","unstructured":"Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008; 111: 4355\u20134364.","journal-title":"Blood"},{"key":"BFbcj201530_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/leu.2011.285","volume":"26","author":"DH Mak","year":"2012","unstructured":"Mak DH, Wang R-Y, Schober WD, Konopleva M, Cortes J, Kantarjian H et al. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 2012; 26: 788\u2013794.","journal-title":"Leukemia"},{"key":"BFbcj201530_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","volume":"12","author":"DJ Goff","year":"2013","unstructured":"Goff DJ, Court Recart A, Sadarangani A, Chun H-J, Barrett CL, Krajewska M et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 2013; 12: 316\u2013328.","journal-title":"Cell Stem Cell"},{"key":"BFbcj201530_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.exphem.2012.05.010","volume":"40","author":"SE Jalkanen","year":"2012","unstructured":"Jalkanen SE, Lahesmaa-Korpinen A-M, Heckman CA, Rantanen V, Porkka K, Hautaniemi S et al. Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. Exp Hematol 2012; 40: 705\u2013714.e3.","journal-title":"Exp Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201530","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T10:00:15Z","timestamp":1672912815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5]]}},"alternative-id":["BFbcj201530"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2015.30","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,1]]},"assertion":[{"value":"27 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SM has received honoraria and research funding from Novartis and Bristol-Myers Squibb and research funding from Pfizer. KP has received research funding and honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}